Bayer: Science For A Better Life

United States of America

CFG - TKI - GIST

Call For Grant 

Budget: $200,000

Intended Audience:

  • Oncologist
  • Nurses
  • Pharmacist 

Bayer TA Rationale for Educational Support:

  • Role of TKIs in the treatment paradigm and AE management in GIST, including: 
    • considerations for treatment sequencing in Imatinib-refractory GIST
    • Stratification of treatment choices based on molecular subtypes

Preferred Format:  

  • Enduring
  • Downloadable slides
  • Podcast
  • Virtual

Proposal Requirements:

The proposal must be compliant with standards and guidelines for commercial support (e.g., ACCME).
The proposal should include:

  • Needs assessment
  • Educational design and rationale for selection (where applicable)
  • Learning Objectives & Draft Agenda
  • Proposed Faculty
  • Participant recruitment plan (where applicable)
  • Outcomes strategy/plan
  • Detailed budget (please use the template available on the website)

Provider Justification:

Copy of most recent accreditation letter and status

Process:

Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.

Acceptance of a Bayer educational grant indicates that you will: 

  • Provide timely updates on changes in project timeline and event launch date
  • Reconcile grant funding within 60 days of completion of the educational program
  • Permit a Bayer Medical Affairs representative to audit live programs
  • Share activity data and outcomes metrics within 30 days of their availability
     

References:

  1. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Gastrointestinal Stromal Tumors (GIST). Version 1.2021 – October 30, 2020 (link)
  2. Kelly CM et al. The management of metastatic GIST: current standard and investigational therapeutics. J Hematol Oncol. 2021 Jan 5;14(1):2 (link)
  3. Al-Share B, et al. Gastrointestinal stromal tumor: a review of current and emerging therapies. Cancer Metastasis Rev. 2021 Apr 19 (online ahead of print) (link)
  4. George S, Wang Q, Heinrich M, et al. Efficacy and Safety of Regorafenib in Patients with metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial. JCO. 2012 Jul 30 (19): 2401-2407 (link)
  5. Demetri G, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID): an international, multicenter, randomized, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26;381(9863):295-302 (link)
  6. Ben-Ami E et al. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol. 2016 Sep;27(9):1794-9 (link)
  7. Call, JW et al. Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry. Clin Sarcoma Res. 2019 Apr 2;9:4. (link)
  8. Nannini M, et al. Complete radiological response to first-line regorafenib in a patient with abdominal relapse of BRAF V600E mutated GIST. Therap Adv Gastroenterol. 2020 Jun 30 (link)
  9. Grothey, A et al. Exploration of efficacious alternative regorafenib regimens to manage hand-foot-skin-reaction (HFSR); Annals of Oncology 30 (5), October 2019 (link)
  10. Rizzo A, et al. Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis. Ther Adv Med Oncol. 2020 Jul 7;12:1758835920936932 (link)